Episode 740: GT Biopharma ($GTBP) CEO on Expanding Into Solid Tumors and Key 2026 Catalysts
Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this...
Stocks To Watch · Global One Media Pte. Ltd.
Audio is streamed directly from the publisher (pdcn.co) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this interview, GT Biopharma (NASDAQ: GTBP) CEO Michael Breen explains why the company is expanding its platform into solid tumors and how its NK engager technology is designed to activate the body’s natural immune response.
Breen discusses the science behind GTB-5550, why B7H3 is a compelling target across many solid tumors, and how preclinical results support the company’s next steps. He also outlines key milestones from 2025 and what investors should watch as GT Biopharma moves toward clinical trials and data readouts in 2026.
Learn more about GT Biopharma: https://www.gtbiopharma.com/
Watch the full YouTube interview here: https://www.youtube.com/watch?v=I7-Vd8PO8L0
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia